TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37335759

Group type: EXPERIMENTAL
Intervention: Advanced Hybrid Closed-Loop System
Number of subjects: 0
Study: 37335760

Group type: EXPERIMENTAL
Intervention: Power Training 1 day/week (PT1, n = 14)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Power Training 2 days/week (PT2, n = 17)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Power Training 3 days/week (PT3, n = 17)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Wait Control (CON, n = 15)
Number of subjects: 63
Study: 37335817

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program, consisting of 8 weekly sessions lasting 2.5 hours each and a 6-hour silence retreat during week 6.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 90
Study: 37335885

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 37335910

Group type: EXPERIMENTAL
Intervention: Advance care planning conversations (specific details on dosage and duration are not available)
Number of subjects: 0
Study: 37335957

Group type: EXPERIMENTAL
Intervention: nCRT followed by TME surgery
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Up-front surgery
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Low-risk patients (up-front surgery)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: High-risk patients (nCRT followed by TME)
Number of subjects: 1099
Study: 37335960

Group type: EXPERIMENTAL
Intervention: Busulfan plus fludarabine (BuFlu) regimen
Number of subjects: 386

Group type: COMPARATOR
Intervention: Busulfan plus cyclophosphamide (BuCy) regimen
Number of subjects: 386
Study: 37335962

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: intraoperative MRI (iMRI)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 314
Study: 37335963

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered concomitantly (Coad group)
Number of subjects: 545

Group type: COMPARATOR
Intervention: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered sequentially (Seq group)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Coad group (mRNA-1273 and RZV1 concomitantly)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Seq group (mRNA-1273 and RZV1 sequentially)
Number of subjects: 545
Study: 37335970

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D) group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 24
Study: 37335976

Group type: EXPERIMENTAL
Intervention: Pulsed field ablation using the CENTAURI System with TactiCath SE, StablePoint, and ThermoCool ST ablation catheters
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pulsed field ablation development Cohorts 1 and 2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Optimized PFA Cohorts 3-5
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pulsed field ablation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Invasive remapping
Number of subjects: 82
Study: 37335992

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin daily
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 37335994

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Doxylamine-Pyridoxine
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Combination of Acupuncture and Doxylamine-Pyridoxine
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 37335995

Group type: EXPERIMENTAL
Intervention: Combination NRT (fast-acting form plus patch)
Number of subjects: 43327

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 43327

Group type: EXPERIMENTAL
Intervention: Fast-acting form of NRT (gum or lozenge)
Number of subjects: 43327

Group type: EXPERIMENTAL
Intervention: NRT before quitting
Number of subjects: 43327

Group type: EXPERIMENTAL
Intervention: Lower-dose nicotine patches and gum
Number of subjects: 43327

Group type: COMPARATOR
Intervention: NRT (various types)
Number of subjects: 43327
Study: 37336007

Group type: EXPERIMENTAL
Intervention: Online opioid overdose and naloxone administration education (20-minute video)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Naloxone kit possession
Number of subjects: 194

Group type: COMPARATOR
Intervention: Naloxone possession
Number of subjects: 194
Study: 37336055

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel ≤12 mg/day
Number of subjects: 65
Study: 37336058

Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14 monoclonal antibody)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37336228

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 37336535

Group type: EXPERIMENTAL
Intervention: Cognitive symptoms reported by participants with positive COVID-19 test results (self-reported as 'feeling disoriented or having trouble thinking')
Number of subjects: 3908

Group type: EXPERIMENTAL
Intervention: Cognitive symptoms
Number of subjects: 3908

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3908

Group type: EXPERIMENTAL
Intervention: Age (40-49 years)
Number of subjects: 3908

Group type: EXPERIMENTAL
Intervention: History of autoimmune disease
Number of subjects: 3908

Group type: EXPERIMENTAL
Intervention: Lung disease
Number of subjects: 3908

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 3908

Group type: COMPARATOR
Intervention: COVID-19 vaccination before infection
Number of subjects: 3908

Group type: COMPARATOR
Intervention: Black race
Number of subjects: 3908
Study: 37336533

Group type: EXPERIMENTAL
Intervention: Mavacamten (starting dose 2.5 mg/day, adjusted during the study)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 37336835

Group type: EXPERIMENTAL
Intervention: Preventative therapy consultation
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Preventative therapy prescription
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Information on breast cancer risk and prevention
Number of subjects: 182
Study: 37336845

Group type: EXPERIMENTAL
Intervention: Intraoperative flow disruptions (FDs)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Equipment- and patient-related FDs
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Higher rates of FDs
Number of subjects: 61
Study: 37336877

Group type: COMPARATOR
Intervention: mRNA-1010 (50 µg, 100 µg, or 200 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mRNA-1010 (25 µg, 50 µg, or 100 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mRNA-1010
Number of subjects: 0
Study: 37337060

Group type: EXPERIMENTAL
Intervention: Genicular artery embolisation (GAE) using 100-micron Embozene™ microspheres
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham procedure using 0.9% saline
Number of subjects: 110
Study: 37337059

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization with HepaSphere™ Microspheres 30-60 μm loaded with irinotecan (IRI-HEP-TACE)
Number of subjects: 100
Study: 37337155

Group type: EXPERIMENTAL
Intervention: FOLFIRI-Ram (5-FU 2400 mg/m2)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Paclitaxel and ramucirumab
Number of subjects: 429
Study: 37337181

Group type: EXPERIMENTAL
Intervention: Standard pay-it-forward intervention of gonorrhea/chlamydia testing with minimal encouragement for testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-engaged pay-it-forward arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm where men pay for their tests out-of-pocket
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 37337208

Group type: EXPERIMENTAL
Intervention: Caregivers FIRST program (adopters)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-adopters
Number of subjects: 63
Study: 37337222

Group type: EXPERIMENTAL
Intervention: Immediate disclosure of genetic risk information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred disclosure of genetic risk information
Number of subjects: 0
Study: 37337234

Group type: EXPERIMENTAL
Intervention: High protein content (2.0 g of protein/kg/day)
Number of subjects: 935

Group type: COMPARATOR
Intervention: Standard protein content (1.3 g of protein/kg/day)
Number of subjects: 935
Study: 37337243

Group type: EXPERIMENTAL
Intervention: Extracorporeal hemoadsorption with VV ECMO
Number of subjects: 100
Study: 37337261

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment As Usual (TAU)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) alone
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 136
Study: 37337269

Group type: EXPERIMENTAL
Intervention: Periradicular administration of platelet-rich fibrin (PRF) during surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 60
Study: 37337295

Group type: EXPERIMENTAL
Intervention: Inhaled xenon administered within 6 hours after the onset of symptoms of aSAH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37337366

Group type: EXPERIMENTAL
Intervention: Cotadutide 600-μg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 37337526

Group type: EXPERIMENTAL
Intervention: Psilocybin 25mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Psilocybin 1mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 59
Study: 37337747

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Glimepiride 1-2 mg/day
Number of subjects: 124
Study: 37337860

Group type: EXPERIMENTAL
Intervention: Preeclampsia (PE) children
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Late-onset PE children
Number of subjects: 267

Group type: COMPARATOR
Intervention: Non-PE children
Number of subjects: 267
Study: 37337896

Group type: EXPERIMENTAL
Intervention: Seattle HF Model (SHFM)
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: HF Meta-Score
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Meta-Analysis Global Group in Chronic Heart Failure
Number of subjects: 1643

Group type: COMPARATOR
Intervention: HF cardiologists
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Family doctors
Number of subjects: 1643
Study: 37337948

Group type: EXPERIMENTAL
Intervention: Strength training intervention
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Bioelectrical phase angle (PhA) measurement
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 158
Study: 37338010

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 90
Study: 37338017

Group type: COMPARATOR
Intervention: 0.1-20.0 g/day alcohol use (moderate drinkers)
Number of subjects: 58769

Group type: EXPERIMENTAL
Intervention: >20.0 g/day alcohol use (heavy drinkers)
Number of subjects: 58769

Group type: EXPERIMENTAL
Intervention: 0.0 g/day alcohol use (non-drinkers)
Number of subjects: 58769
Study: 37338130

Group type: EXPERIMENTAL
Intervention: Telemedicine for Reach, Education, Access, Treatment, and Ongoing Support (TREAT-ON) program
Number of subjects: 30

Group type: COMPARATOR
Intervention: In-person DSMES delivered by a Diabetes Care and Education Specialist (DCES)
Number of subjects: 30
Study: 37338150

Group type: EXPERIMENTAL
Intervention: Senaparib (100 mg QD)
Number of subjects: 57
Study: 37338154

Group type: EXPERIMENTAL
Intervention: MAS825 (10 mg/kg single i.v.) + standard of care (SoC)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo + standard of care (SoC)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: MAS825 + SoC
Number of subjects: 138
Study: 37338158

Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 274

Group type: COMPARATOR
Intervention: PCV13 (Prevnar 13)
Number of subjects: 274
Study: 37338163

Group type: EXPERIMENTAL
Intervention: Computer-based cervical kinesthetic exercise (CKE) program
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Neck exercises provided by the corresponding physical therapist
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study: 37338335

Group type: EXPERIMENTAL
Intervention: Automatic sleep staging system (ASSS) utilizing photoplethysmography and acceleration data from a smartwatch (MT2511)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Actiwatch Spectrum Plus
Number of subjects: 75

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 75
Study: 37338355

Group type: EXPERIMENTAL
Intervention: Radiomics features in standard-dose CT (model I)
Number of subjects: 8878

Group type: COMPARATOR
Intervention: Demographics in standard-dose CT
Number of subjects: 8878
Study: 37338393

Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir, an oral antiviral drug targeting viral RNA polymerase, dosage and duration not specified.
Number of subjects: 0
Study: 37338442

Group type: EXPERIMENTAL
Intervention: Open label phase following the RCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypnosis, mindfulness meditation, and pain education (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-open label phase assessments
Number of subjects: 0
Study: 37338445

Group type: EXPERIMENTAL
Intervention: Prolonged exposure treatment focusing on sexual assault trauma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged exposure treatment not focusing on sexual assault trauma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with SA history
Number of subjects: 0
Study: 37338535

Group type: EXPERIMENTAL
Intervention: AR-guided laparoscopic pancreaticoduodenectomy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-AR laparoscopic pancreaticoduodenectomy
Number of subjects: 82
Study: 37338608

Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation with oral bisphosphonate, calcium and/or vitamin D
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 105
Study: 37338615

Group type: EXPERIMENTAL
Intervention: Clonidine (75 μg twice a day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 37338627

Group type: EXPERIMENTAL
Intervention: Nurse AMIE (Addressing Metastatic Individuals Everyday) for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (unexposed for the first 3 months)
Number of subjects: 42
Study: 37338729

Group type: EXPERIMENTAL
Intervention: Abemaciclib (not specified dosage or duration)
Number of subjects: 1617
Study: 37338893

Group type: EXPERIMENTAL
Intervention: ApTOLL 0.2 mg/kg
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: ApTOLL 0.05 mg/kg
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 37338898

Group type: EXPERIMENTAL
Intervention: Technology Assisted Stepped Collaborative Care (TĀCcare) - 12 weekly sessions of cognitive behavioral therapy via telehealth and/or pharmacotherapy.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attention control - 6 telehealth sessions of health education.
Number of subjects: 160
Study: 37338906

Group type: EXPERIMENTAL
Intervention: Adapted therapy (ADT) with nicotine patch (NP) and pharmacotherapy adaptations (varenicline and bupropion+NP)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Adapted therapy (ADT) with pharmacotherapy adaptations
Number of subjects: 392
Study: 37338929

Group type: EXPERIMENTAL
Intervention: Remote monitoring solutions and digital alerting tools
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Recommendations for enhancing integration of remote sensing solutions
Number of subjects: 29
Study: 37338972

Group type: EXPERIMENTAL
Intervention: Neck-specific exercises with internet support (NSEIT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Neck-specific exercises supervised by a physiotherapist (NSE)
Number of subjects: 140
Study: 37338977

Group type: EXPERIMENTAL
Intervention: TCM mHealth app (n=42)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ordinary mHealth app (n=41)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 121
Study: 37339000

Group type: EXPERIMENTAL
Intervention: PWID
Number of subjects: 578

Group type: COMPARATOR
Intervention: Other patients
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Latecomers to clinical visits
Number of subjects: 578
Study: 37339167

Group type: EXPERIMENTAL
Intervention: Presence, extension, and progression of subclinical atherosclerosis
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Accelerated Grim epigenetic age
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Mediation analysis using transcriptomics and proteomics data
Number of subjects: 391
Study: 37339173

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR)-based care pathway
Number of subjects: 312

Group type: COMPARATOR
Intervention: Invasive-based care pathway
Number of subjects: 312
Study: 37339186

Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg daily plus rucaparib 400 mg twice daily
Number of subjects: 51
Study: 37339254

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil 25 mg/m2 (days 1-5 of 14-day cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus irinotecan
Number of subjects: 28
Study: 37339332

Group type: EXPERIMENTAL
Intervention: Dual-release hydrocortisone (DR-HC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Immediate release hydrocortisone (IR-HC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study: 37339334

Group type: EXPERIMENTAL
Intervention: HPT-JT-related parathyroid tumors
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Uterine tumors
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Kidney tumors
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Parafibromin staining of parathyroid tumors
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: RNA-sequencing
Number of subjects: 68
Study: 37339342

Group type: EXPERIMENTAL
Intervention: Impart APN
Number of subjects: 55

Group type: COMPARATOR
Intervention: Self-tell notification (treatment as usual)
Number of subjects: 55
Study: 37339352

Group type: COMPARATOR
Intervention: Light Vibrational Forces (LVF)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Light Emitting Diode (LED)
Number of subjects: 1027
Study: 37339360

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37339363

Group type: EXPERIMENTAL
Intervention: Interdisciplinary Weight Loss and Lifestyle Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37339390

Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR1 (E2 80 μg/d with P4 4 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR2 (E2 160 μg/d with P4 8 mg/d)
Number of subjects: 21
Study: 37339396

Group type: EXPERIMENTAL
Intervention: LEMBOREXANT 5 mg (LEM5)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: LEMBOREXANT 10 mg (LEM10)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 280
Study: 37339441

Group type: EXPERIMENTAL
Intervention: d-Amphetamine Transdermal System
Number of subjects: 0
Study: 37339483

Group type: EXPERIMENTAL
Intervention: CLAG-M/sorafenib
Number of subjects: 81

Group type: COMPARATOR
Intervention: CLAG-M
Number of subjects: 81
Study: 37339586

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus vorinostat (Vorinostat 100 mg twice a day for DL1 and 200 mg twice a day for DL2, administered orally from days 1 to 5 and 8 to 12; Pembrolizumab 200 mg IV every 3 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus vorinostat in patients refractory to prior PD-1 blockade (n=18)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus vorinostat
Number of subjects: 32
Study: 37339820

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention based on Plan-Do-Study-Act cycles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 10
Study: 37339817

Group type: EXPERIMENTAL
Intervention: rtfMRI-nf training to increase amygdala responses during positive memory recall
Number of subjects: 38

Group type: COMPARATOR
Intervention: Parietal responses during positive autobiographical memory recall (control group)
Number of subjects: 38
Study: 37339979

Group type: EXPERIMENTAL
Intervention: GVAX vaccine with low-dose cyclophosphamide (Arm A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GVAX vaccine with anti-PD-1 antibody nivolumab (Arm B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GVAX vaccine with nivolumab and anti-CD137 agonist antibody urelumab (Arm C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GVAX+nivolumab+urelumab (Arm C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GVAX (Arm A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GVAX+nivolumab (Arm B)
Number of subjects: 40
Study: 37340107

Group type: EXPERIMENTAL
Intervention: Distal Gastrectomy (DG)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Total Gastrectomy (TG)
Number of subjects: 211
Study: 37340170

Group type: EXPERIMENTAL
Intervention: 4-session intervention including safety plans with mobile augmentation
Number of subjects: 53

Group type: COMPARATOR
Intervention: 4-session intervention including safety plans without mobile augmentation
Number of subjects: 53
Study: 37340213

Group type: EXPERIMENTAL
Intervention: Dog-assisted Therapy (DAT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Relaxation (control group)
Number of subjects: 71